US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) – Forecasts to 2021

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: March 23, 2020
Clear
SKU: GMS-3065 Category:

The US Therapeutic Plasma Exchange Market is expected to hit USD 374.14 million by 2025, rising by 10.82% to CAGR during the forecast period. Factors such as increasing neurological disease prevalence, increasing the adoption of TPE procedures in rare disorders and increasing awareness of the increasing clinical response rate of TPE procedures in various diseases in the US are driving demand for the US Therapeutic Plasma Exchange Market.

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 1

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 2

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 3

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 4

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 5

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 6

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 7

US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) - Forecasts to 2021 8

1 US Therapeutic Plasma Exchange Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 US Therapeutic Plasma Exchange Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 US Therapeutic Plasma Exchange Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 US Therapeutic Plasma Exchange Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 US Therapeutic Plasma Exchange Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 US Therapeutic Plasma Exchange Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 US Therapeutic Plasma Exchange Market – By Procedures & Patients (Market Size – &
million/billion)
8.1 Guillain-Barré Syndrome (GBS)
8.2 Thrombotic Thrombocytopenic Purpura (TTP)
8.3 Cryoglobulinemia
8.4 Multiple Myeloma (MM)
8.5 Waldenstrom Macroglobulinemia (WM)
8.6 Myasthenia Gravis (MG)
8.7 Multiple Sclerosis (MS)
8.8 Neuromyelitis Optica (NMO)
8.9 Post-Renal Transplant Rejection
8.10 Familial Hypercholesterolemia (Homozygous)
8.11 Others

9 US Therapeutic Plasma Exchange Market – By Indication
9.1 Autoimmune Disorders
9.2 Neurological Disorders

10 US Therapeutic Plasma Exchange Market – Entropy
10.1 New product launches
10.2 M&A’s, collaborations, JVs and partnerships

11 US Therapeutic Plasma Exchange Market – Company Profile (Key Players)
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 Haemonetics Corporation
11.3 Kawasumi Laboratories, Inc.
11.4 Baxter International Inc
11.5 Asahi Kasei Medical Co., Ltd.
11.6 Terumo BCT, Inc.
11.7 Hemacare Corporation
11.8 Fresenius Se & Co. KGAA
11.9 B. Braun Melsungen AG
11.10 Company 9
11.11 Company 10
11.12 Company 11 & more

12 US Therapeutic Plasma Exchange Market – Appendix
12.1 Sources
12.2 Abbreviations